Clioquinol, a Therapeutic Agent for Alzheimer's Disease, Has Proteasome-Inhibitory, Androgen Receptor-Suppressing, Apoptosis-Inducing, and Antitumor Activities in Human Prostate Cancer Cells and Xenografts

doi:10.1158/0008-5472.CAN-06-3546

Title: Clioquinol, a Therapeutic Agent for Alzheimer's Disease, Has Proteasome-Inhibitory, Androgen Receptor-Suppressing, Apoptosis-Inducing, and Antitumor Activities in Human Prostate Cancer Cells and Xenografts

Full Record
Other Related Research

Authors:: Chen, D.; Cui, Q. C.; Yang, H.; Barrea, R. A.; Sarkar, F. H.; Sheng, S.; Yan, B.; Reddy, G. P. V.; Dou, Q. P.

Publication Date:: Thu Feb 15 00:00:00 EST 2007

Research Org.:: Argonne National Lab. (ANL), Argonne, IL (United States). Advanced Photon Source (APS)

Sponsoring Org.:: OTHERUNIVERSITYNIH

OSTI Identifier:: 1127255

Resource Type:: Journal Article

Resource Relation:: Journal Name: Cancer Research; Journal Volume: 67; Journal Issue: 4

Country of Publication:: United States

Language:: ENGLISH

Citation Formats


                    Chen, D., Cui, Q. C., Yang, H., Barrea, R. A., Sarkar, F. H., Sheng, S., Yan, B., Reddy, G. P.  V., and Dou, Q. P.. Clioquinol, a Therapeutic Agent for Alzheimer's Disease, Has Proteasome-Inhibitory, Androgen Receptor-Suppressing, Apoptosis-Inducing, and Antitumor Activities in Human Prostate Cancer Cells and Xenografts.  United States: N. p., 2007. 
        Web.  doi:10.1158/0008-5472.CAN-06-3546.

Copy to clipboard


                    Chen, D., Cui, Q. C., Yang, H., Barrea, R. A., Sarkar, F. H., Sheng, S., Yan, B., Reddy, G. P.  V., & Dou, Q. P.. Clioquinol, a Therapeutic Agent for Alzheimer's Disease, Has Proteasome-Inhibitory, Androgen Receptor-Suppressing, Apoptosis-Inducing, and Antitumor Activities in Human Prostate Cancer Cells and Xenografts.  United States.  doi:10.1158/0008-5472.CAN-06-3546.

Copy to clipboard


                    Chen, D., Cui, Q. C., Yang, H., Barrea, R. A., Sarkar, F. H., Sheng, S., Yan, B., Reddy, G. P.  V., and Dou, Q. P.. Thu .  
        "Clioquinol, a Therapeutic Agent for Alzheimer's Disease, Has Proteasome-Inhibitory, Androgen Receptor-Suppressing, Apoptosis-Inducing, and Antitumor Activities in Human Prostate Cancer Cells and Xenografts".  United States.  
        doi:10.1158/0008-5472.CAN-06-3546.

Copy to clipboard


                    
@article{osti_1127255,

  title        = {Clioquinol, a Therapeutic Agent for Alzheimer's Disease, Has Proteasome-Inhibitory, Androgen Receptor-Suppressing, Apoptosis-Inducing, and Antitumor Activities in Human Prostate Cancer Cells and Xenografts},

  author       = {Chen, D. and Cui, Q. C. and Yang, H. and Barrea, R. A. and Sarkar, F. H. and Sheng, S. and Yan, B. and Reddy, G. P.  V. and Dou, Q. P.},

  abstractNote = {},

  doi          = {10.1158/0008-5472.CAN-06-3546},

  journal      = {Cancer Research},

  number       = 4,

  volume       = 67,

  place        = {United States},

  year         = {Thu Feb 15 00:00:00 EST 2007},

  month        = {Thu Feb 15 00:00:00 EST 2007}

}

Copy to clipboard

Journal Article:

DOI: 10.1158/0008-5472.CAN-06-3546

Other availability

Find in Google Scholar

Search WorldCat to find libraries that may hold this journal

Save / Share:

Export Metadata

Save to My Library

Similar records in OSTI.GOV collections:

The PPAR{gamma} ligand ciglitazone regulates androgen receptor activation differently in androgen-dependent versus androgen-independent human prostate cancer cells

Journal Article Moss, Patrice E. ; Lyles, Besstina E. ; Stewart, LaMonica V., E-mail: lstewart@mmc.edu - Experimental Cell Research

The androgen receptor (AR) regulates growth and progression of androgen-dependent as well as androgen-independent prostate cancer cells. Peroxisome proliferator-activated receptor gamma (PPAR{gamma}) agonists have been reported to reduce AR activation in androgen-dependent LNCaP prostate cancer cells. To determine whether PPAR{gamma} ligands are equally effective at inhibiting AR activity in androgen-independent prostate cancer, we examined the effect of the PPAR{gamma} ligands ciglitazone and rosiglitazone on C4-2 cells, an androgen- independent derivative of the LNCaP cell line. Luciferase-based reporter assays and Western blot analysis demonstrated that PPAR{gamma} ligand reduced dihydrotestosterone (DHT)-induced increases in AR activity in LNCaP cells. However, in C4-2 cells,more »« less
DOI: 10.1016/J.YEXCR.2010.09.015
Crystal Structures of AKR1C3 Containing an N-(aryl)amino-benzoate Inhibitor and a Bifunctional AKR1C3 Inhibitor and Androgen Receptor Antagonist. Therapeutic Leads for Castrate Resistant Prostate Cancer

Journal Article Chen, M ; Adeniji, A ; Twenter, B ; ... - BioOrganic and Medicinal Chemistry Letters
DOI: 10.1016/j.bmcl.2012.03.085
The liver X receptor agonist T0901317 acts as androgen receptor antagonist in human prostate cancer cells

Journal Article Chuu, Chih-pin ; Chen, Rou-Yu ; Hiipakka, Richard A. ; ... - Biochemical and Biophysical Research Communications

T0901317 is a potent non-steroidal synthetic liver X receptor (LXR) agonist. T0901317 blocked androgenic stimulation of the proliferation of androgen-dependent LNCaP 104-S cells and androgenic suppression of the proliferation of androgen-independent LNCaP 104-R2 cells, inhibited the transcriptional activation of an androgen-dependent reporter gene by androgen, and suppressed gene and protein expression of prostate specific antigen (PSA), a target gene of androgen receptor (AR) without affecting gene and protein expression of AR. T0901317 also inhibited binding of a radiolabeled androgen to AR, but inhibition was much weaker compared to the effect of the antiandrogens, bicalutamide and hydroxyflutamide. The LXR agonist T0901317,more »« less
DOI: 10.1016/j.bbrc.2007.03.116
Disulfiram, a Clinically Used Anti-Alcoholism Drug and Copper-Binding Agent, Induces Apoptotic Cell Death in Breast Cancer Cultures and Xenografts via Inhibition of the Proteasome Activity

Journal Article Chen, Di ; Cui, Qiuzhi Cindy ; Yang, Huanjie ; ... - Cancer Res.
DOI: 10.1158/0008-5472.CAN-06-2126
Bone stroma-derived cells change coregulators recruitment to androgen receptor and decrease cell proliferation in androgen-sensitive and castration-resistant prostate cancer cells

Journal Article Villagran, Marcelo A. ; Gutierrez-Castro, Francisco A. ; Pantoja, Diego F. ; ... - Biochemical and Biophysical Research Communications

Prostate cancer (CaP) bone metastasis is an early event that remains inactive until later-stage progression. Reduced levels of circulating androgens, due to andropause or androgen deprivation therapies, alter androgen receptor (AR) coactivator expression. Coactivators shift the balance towards enhanced AR-mediated gene transcription that promotes progression to androgen-resistance. Disruptions in coregulators may represent a molecular switch that reactivates latent bone metastasis. Changes in AR-mediated transcription in androgen-sensitive LNCaP and androgen-resistant C4-2 cells were analyzed for AR coregulator recruitment in co-culture with Saos-2 and THP-1. The Saos-2 cell line derived from human osteosarcoma and THP-1 cell line representing human monocytes were usedmore »« less
DOI: 10.1016/J.BBRC.2015.10.009

Similar Records